New Survey Shows Barriers in Legal Medical Cannabis System Forcing Patients to Self-Medicate Without HCP Support

Published: October 16, 2020

New Survey Shows Barriers in Legal Medical Cannabis System Forcing Patients to Self-Medicate Without HCP Support

Medical Cannabis Canada (MCC) today announces the results of its first Medical Cannabis Patient Survey (MCPS), which found that systemic barriers in the legal medical cannabis system are pushing patients to unregulated and recreational markets without the support of a health care professional.

In Canada, cannabis can be legally accessed recreationally or medically. The medical system requires a “medical document” (similar to a prescription) from a health care practitioner. The MCPS found that only 37% of Canadians using cannabis for medical purposes have a medical document. This is concerning since patients without a medical document report substantially less engagement with h­ealth care professionals and more report use of unregulated markets to access their treatment.

The MCPS reports that 74% of those who have had a medical document go to a healthcare practitioner or a pharmacist for guidance on cannabis use for medical purposes, compared to just 24% of those who have never had a medical document. This confirms that most patients are self-medicating without expert support.

“It is essential for Canadians to have access to support from health care professionals to help them navigate medical cannabis safely and effectively. Unfortunately, there is little incentive to access a medical document or use the legal medical channel and many are being left to manage their treatment alone,” said Max Monahan-Ellison, Medical Cannabis Canada Board Member and MCPS Project Lead.

The majority of patients who have never had a medical document report going to friends and family, websites, and retail salespeople or “budtenders” at recreational cannabis stores for medical guidance. Only a small proportion of these patients have spoken to a health care practitioner about potential drug interactions with cannabis.

Most patients (83%) feel there is stigma among traditional medical practitioners surrounding medical cannabis use and 57% struggle to find a health care practitioner to speak to about getting a medical document. What’s more, 60% say they feel like they have to access medical cannabis from the unregulated market because the regulated system poses too many challenges, including cost, barriers to obtaining a medical document, and difficulty navigating the structure.

Cost was seen as the biggest barrier pushing patients to abandon the medical cannabis system and is the main reason patients switch sources. In the past year, most patients reported using the recreational market to access their treatment, 24% from an unregulated dispensary and 33% informally through a friend, family, acquaintance or dealer. These unregulated sources were perceived as more affordable than accessing medical cannabis through legal channels for purchase.

These barriers can have negative impacts on patients. While 1 in 4 reported that increased medical cannabis use decreased reliance on opioid pain relievers, 36% of these patients reported that barriers to accessing medical cannabis led them to return to opioid medications.

“As the Cannabis Act comes up for review in 2021, collaborative efforts are needed by the industry, non-profits and regulators to ensure patients can access their treatment and health care professional support,” added Max Monahan-Ellison.

Two key areas need to be addressed:

  • Expanding access points to medical cannabis through pharmacy distribution, in addition to existing mail delivery options:
    • Around 90% of patients say they are supportive of pharmacists being able to issue medical documents, dispense medical cannabis, and provide medical guidance on cannabis use and risk, with 1 in 3 saying being able access to this guidance would encourage them to speak to a health care practitioner.
  • Improving affordability, with a focus on eliminating excise duty, HST/GST and PST (in applicable provinces) and pushing for the expansion of benefits coverage:
    • Over 90% of patients say they are supportive of the elimination of taxes on medical cannabis, with nearly 60% saying they think this would reduce the costs of their treatment and around a quarter saying it would reduce their use of the unregulated market.

Visit to download the results report.

About the Medical Cannabis Patient Survey (MCPS)

The survey was conducted among 1,000 medical cannabis patients from July 28, 2020 to August 1, 2020. A random sample of panelists were invited to complete the survey from a set of partner panels based on the Lucid exchange platform. These partners are typically double opt in survey panels, blended to manage out potential skews in the data from a single source. The margin of error for a comparable probability based random sample of the same size is +/ 3.08%, 19 times out of 20.

The data were weighted according to census data to ensure that the sample matches the medical cannabis patient population to age, gender, region, and whether or not they hold a medical document. Analysis from a second sample of 1,785 people from the Medical Cannabis Canada network is not included within this release.

Medical Cannabis Canada would like to thank Spectrum Therapeutics, the medical division of Canopy Growth Corporation for helping make this important project possible through an arms-length unrestricted grant to MCC. With this support, MCC had full control over the protocol, development and results.

Visit for more information.

About MCC

Medical Cannabis Canada (MCC) is a national non-profit patient advocacy organization whose mission is to advance the outcomes of all medical cannabis patients and ensure they can access their treatment safely, equitably and with the support of health care professionals. Formerly known as Canadians for Fair Access to Medical Marijuana (CFAMM), MCC was founded in 2014 and has over 16,000 patients, allies, and stakeholders in its network. For more information, visit